Autres langues Galmed Pharmaceuticals Ltd.

Actions

GLMD

IL0011313900

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 30/04/2024			Varia. 5j.	Varia. 1 janv.
0,352 ^USD	-7,12%		-2,60%	-22,64%

04/04	Galmed Pharmaceuticals Ltd. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
15/03	Galmed Pharmaceuticals Ltd. annonce la délivrance d'un nouveau brevet pour l'association d'Aramchol et de Resmetirom (MGL-3196, REZDIFFRA) dans le traitement de la Nash et de la fibrose hépatique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/04
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	15/03
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis	15/03
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K	22/11
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	22/11
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	21/11
Sector Update: Health Care	21/11
Top Midday Decliners	21/11
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study	20/11
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study	20/11
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis	26/09/23
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	25/09/23
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	22/09/23
Galmed Pharmaceuticals: Q2 Earnings Snapshot	10/08/23
Galmed Pharmaceuticals : 16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K	09/08/23
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Galmed Pharmaceuticals : Securities Purchase Agreement - Form 6-K	18/07/23
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering	17/07/23
Top Midday Decliners	14/07/23
Galmed Pharmaceuticals Prices $7 Million Securities Offering; Shares Slump	14/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Galmed Pharmaceuticals Ltd.

Actions

GLMD

IL0011313900

Autres langues

Filtres